B cell maturation antigen–specific CAR T cells are clinically active in multiple myeloma

10.1111/j.1600-065X.2011.01067.x

10.1182/blood-2013-09-529800

10.1182/blood-2013-10-535088

10.1158/1078-0432.CCR-12-2422

10.1016/j.ccell.2017.02.002

Laurent, 2015, γ-Secretase directly sheds the survival receptor BCMA from plasma cells, Nat Commun, 6, 10.1038/ncomms8333

10.1111/j.1365-2141.2012.09241.x

10.1182/blood-2003-06-1984

10.1182/blood-2016-01-691162

10.1056/NEJMoa1504542

Garfall, 2018, Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma, JCI Insight, 3, 10.1172/jci.insight.120505

10.1182/blood-2016-04-711903

10.1126/scitranslmed.aaf8621

10.1056/NEJMoa1407222

Bu, 2018, Pre-clinical validation of B cell maturation antigen (BCMA) as a target for T cell immunotherapy of multiple myeloma, Oncotarget, 9, 25764, 10.18632/oncotarget.25359

10.1126/scitranslmed.aac5415

10.1158/2159-8290.CD-16-0040

10.1038/s41591-018-0010-1

10.1038/nm.4241

10.1200/JCO.2018.77.8084

10.1182/blood.V98.1.23

10.1084/jem.20031030

10.1038/leu.2016.84

10.1200/JCO.2008.16.5449

10.1126/scitranslmed.aaa7014

10.1038/nm.3910

10.1038/nri1842

10.1016/j.leukres.2018.07.015

10.1038/mt.2009.83

10.1172/JCI85309

10.1200/JCO.2014.56.2025

10.1158/2159-8290.CD-17-0698

10.1038/s41591-018-0041-7

10.1038/s41591-018-0036-4

Kalos, 2011, T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia, Sci Transl Med, 3, 10.1126/scitranslmed.3002842

10.1182/blood-2003-01-0095

10.1073/pnas.0608138103

10.1016/S1470-2045(16)30206-6

10.1038/leu.2017.29